These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
4. Racial Differences in Clinical Outcomes for Metastatic Renal Cell Carcinoma Patients Treated With Immune-Checkpoint Blockade. Olsen TA; Martini DJ; Goyal S; Liu Y; Evans ST; Magod B; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Harris WB; Kucuk O; Carthon BC; Master VA; Nazha B; Bilen MA Front Oncol; 2021; 11():701345. PubMed ID: 34222024 [TBL] [Abstract][Full Text] [Related]
5. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726 [TBL] [Abstract][Full Text] [Related]
6. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Quhal F; Mori K; Bruchbacher A; Resch I; Mostafaei H; Pradere B; Schuettfort VM; Laukhtina E; Egawa S; Fajkovic H; Remzi M; Shariat SF; Schmidinger M Eur Urol Oncol; 2021 Oct; 4(5):755-765. PubMed ID: 33757737 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma. Brown LC; Zhu J; Desai K; Kinsey E; Kao C; Lee YH; Pabla S; Labriola MK; Tran J; Dragnev KH; Tafe LJ; Dayyani F; Gupta RT; McCall S; George DJ; Glenn ST; Nesline MK; George S; Zibelman M; Morrison C; Ornstein MC; Zhang T J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36252996 [TBL] [Abstract][Full Text] [Related]
9. Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. Yang Y; Psutka SP; Parikh AB; Li M; Collier K; Miah A; Mori SV; Hinkley M; Tykodi SS; Hall E; Thompson JA; Yin M Cancer Med; 2022 Aug; 11(16):3106-3114. PubMed ID: 35304832 [TBL] [Abstract][Full Text] [Related]
10. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Barata P; Hatton W; Desai A; Koshkin V; Jaeger E; Manogue C; Cotogno P; Light M; Lewis B; Layton J; Sartor O; Basu A; Kilari D; Emamekhoo H; Bilen MA Front Oncol; 2020; 10():581189. PubMed ID: 33194712 [No Abstract] [Full Text] [Related]
11. Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Thana M; Basappa NS; Ghosh S; Kollmannsberger CK; Heng DYC; Hansen AR; Graham J; Soulières D; Reaume MN; Lalani AA; Castonguay V; Bjarnason GA; Patenaude F; Breau RH; Pouliot F; Kapoor A; Wood LA Clin Genitourin Cancer; 2022 Jun; 20(3):210-218. PubMed ID: 35115252 [TBL] [Abstract][Full Text] [Related]
12. Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Brown JT; Liu Y; Shabto JM; Martini D; Ravindranathan D; Hitron EE; Russler GA; Caulfield S; Yantorni L; Joshi SS; Kissick H; Ogan K; Nazha B; Carthon BC; Kucuk O; Harris WB; Master VA; Bilen MA J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326170 [TBL] [Abstract][Full Text] [Related]
13. Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study. Kato T; Fujita K; Minami T; Nagahara A; Hyashi Y; Nakata W; Matsuzaki K; Nakano K; Hatano K; Kawashima A; Imamura R; Takada S; Nishimura K; Tsujihata M; Takao T; Nakai Y; Nakayama M; Nishimura K; Uemura M; Uemura H; Nonomura N Int J Clin Oncol; 2022 Oct; 27(10):1596-1604. PubMed ID: 35831538 [TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab. Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292 [TBL] [Abstract][Full Text] [Related]
15. Outcomes With Combination Pembrolizumab and Axitinib in Second and Further Line Treatment of Metastatic Renal Cell Carcinoma. Dizman N; Austin M; Considine B; Jessel S; Schoenfeld D; Merl MY; Hurwitz M; Sznol M; Kluger H Clin Genitourin Cancer; 2023 Apr; 21(2):221-229. PubMed ID: 36681606 [TBL] [Abstract][Full Text] [Related]
16. The Efficacy and Safety of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor Combination Therapy for Advanced or Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Real-World Cohort Study. Iinuma K; Yamada T; Kameyama K; Taniguchi T; Kawada K; Ishida T; Nagai S; Enomoto T; Ueda S; Takagi K; Kawase M; Takeuchi S; Kawase K; Kato D; Takai M; Nakane K; Koie T Cancers (Basel); 2023 Feb; 15(3):. PubMed ID: 36765903 [TBL] [Abstract][Full Text] [Related]
17. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. Kankkunen E; Penttilä P; Peltola K; Bono P Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053 [TBL] [Abstract][Full Text] [Related]
18. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma. Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260 [TBL] [Abstract][Full Text] [Related]
19. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820 [TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Foster CC; Couey MA; Kochanny SE; Khattri A; Acharya RK; Tan YC; Brisson RJ; Leidner RS; Seiwert TY Cancer; 2021 Dec; 127(24):4565-4573. PubMed ID: 34547103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]